IDEAYA Biosciences Inc. (NASDAQ: IDYA) enrolled the first patient in a phase 1 trial of IDE034, an investigational cancer treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE